We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Results 1 to 5 of 14
Most popular |Most recent


New CFIUS Pilot Program: What Life Sciences Companies and Investors Need to Know

USA - October 29 2018 As many life sciences companies and investors are aware, the U.S. Department of the Treasury (“Treasury”) recently announced a new “pilot program” for...

Nicholas J. Spiliotes, Charles C. Comey, Charles L. Capito III, John P. Carlin, Robert S. Litt, Amy S. Josselyn, Panagiotis C. Bayz.


2016 biometer shows strength in early and late stage deals but cracks beneath the surface

USA - March 30 2017 The 2016 BioMeter showed strength at both ends of the drug-development spectrum, with extremely strong results for pre-clinicaldiscovery transactions...

Allison Lauterbach Dale.


2015 Biometer Shows Tale of Two Markets

USA - May 16 2016 The full-year 2015 BioMeter paints the picture of a strong year for biotechnology, but deeper analysis shows a cautionary trend. The average BioMeter...

Allison Lauterbach Dale, Aaron J. Schohn.


Record 2014 BioMeter shows strong year for biotech

USA - April 29 2015 The full-year 2014 BioMeter confirms that 2014 was a banner year for biotechnology. The average BioMeter value for the entire year across all...

Aaron J. Schohn.


Q3 BioMeter shows reemergence of late stage deals

USA - October 27 2014 The average BioMeter value in the third quarter of 2014 was $43.7 million, an increase from the $30.4 million value in thesame quarter in 2013, and a...

Aaron J. Schohn.